Pliant Therapeutics

OverviewSuggest Edit

Pliant Therapeutics is a company focused on discovering, developing, and commercializing treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, the company aims to prevent or reverse fibrosis to address the needs of patients. It also builds a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.

TypePrivate
Founded2016
HQSouth San Francisco, US
Websitepliantrx.com

Latest Updates

Employees (est.) (Oct 2020)72(+3%)
Job Openings15
Share Price (Oct 2020)$23.8 (+4%)
Cybersecurity ratingAMore

Key People/Management at Pliant Therapeutics

Bernard Coulie

Bernard Coulie

President and Chief Executive Officer, Board Member
Éric Lefebvre

Éric Lefebvre

Chief Medical Officer
Hans Hull

Hans Hull

Chief Business Officer
Katerina Leftheris

Katerina Leftheris

Vice President, Chemistry
Barbara Howes

Barbara Howes

Chief Human Resource Officer
Keith Cummings

Keith Cummings

Chief Financial Officer
Show more

Pliant Therapeutics Office Locations

Pliant Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
260 Littlefield Ave
Show all (1)

Pliant Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Pliant Therapeutics total Funding

$107 m

Pliant Therapeutics latest funding size

$62 m

Time since last funding

2 years ago

Pliant Therapeutics investors

Pliant Therapeutics's latest funding round in July 2018 was reported to be $62 m. In total, Pliant Therapeutics has raised $107 m
Show all financial metrics

Pliant Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Pliant Therapeutics Online and Social Media Presence

Embed Graph

Pliant Therapeutics News and Updates

Pliant Therapeutics Presents Data at The Digital International Liver Congress™ 2020

SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the company will be presenting data at The Digital...

Pliant Therapeutics shares soar 55% in trading debut

Pliant Therapeutics Inc. shares soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range. The company sold 9 million shares to raise $144 million. The deal was upsized from an earlier plan to issue just 6 mi…

Pliant Therapeutics prices IPO at top of estimated range to raise $144 million

Pliant Therapeutics prices IPO at top of estimated range to raise $144 million

Pliant Therapeutics Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 2, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the pricing of its initial public offering of 9,000,000...

Pliant Therapeutics increases size of planned IPO to 9 million shares from 6 million

Pliant Therapeutics Inc. upsized its planned initial public offering on Tuesday, saying in a regulatory filing that it plans to offer 9 million shares, up from an earlier 6 million. The shares are expected to price at $14 to $16, raising $144 million at the top of the range. Citigroup, Cowen, Piper…

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 /PRNewswire/ -- Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...

Pliant Therapeutics Blogs

Senior Analyst/ Manager, Financial Planning and Analysis

Description: Pliant Therapeutics is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapies for fibrotic diseases. Founded by Third Rock Ventures with world-renowned academic thought leaders, Pliant is raising the bar for progress to meet unmet medical …

Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis

The post Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis appeared first on Pliant.

Associate Director/ Director, Formulation Development

Description: Pliant Therapeutics is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapies for fibrotic diseases.  Founded by Third Rock Ventures with world-renowned academic thought leaders, Pliant is raising the bar for progress to address unmet medi…

Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis Preclinical Studies Demonstrating Anti-fibrotic Effect of Integrin Inhibitor to be Presented at American Thoracic Society International Conference

The post Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis <br/> <span style="color: #CCC; font-weight: normal; font-size:12px;"><em>Preclinical Studies Demonstrating Anti-fibrotic Effect of Int…

Pliant Therapeutics Presents Data in Human NASH Liver Tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL)

The post Pliant Therapeutics Presents Data in Human NASH Liver Tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL) appeared first on Pliant.

Senior Clinical Research Associate

The post Senior Clinical Research Associate appeared first on Pliant.
Show more

Pliant Therapeutics Frequently Asked Questions

  • When was Pliant Therapeutics founded?

    Pliant Therapeutics was founded in 2016.

  • Who are Pliant Therapeutics key executives?

    Pliant Therapeutics's key executives are Bernard Coulie, Éric Lefebvre and Hans Hull.

  • How many employees does Pliant Therapeutics have?

    Pliant Therapeutics has 72 employees.

  • Who are Pliant Therapeutics competitors?

    Competitors of Pliant Therapeutics include Xenikos, Angion Biomedica and Kadmon.

  • Where is Pliant Therapeutics headquarters?

    Pliant Therapeutics headquarters is located at 260 Littlefield Ave, South San Francisco.

  • Where are Pliant Therapeutics offices?

    Pliant Therapeutics has an office in South San Francisco.

  • How many offices does Pliant Therapeutics have?

    Pliant Therapeutics has 1 office.